Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge

Influenza HA is the primary target of neutralizing antibodies during infection, and its sequence undergoes genetic drift and shift in response to immune pressure. The receptor binding HA1 subunit of HA shows much higher sequence variability relative to the metastable, fusion-active HA2 subunit, presumably because neutralizing antibodies are primarily targeted against the former in natural infection. We have designed an HA2-based immunogen using a protein minimization approach that incorporates designed mutations to destabilize the low pH conformation of HA2. The resulting construct (HA6) was expressed in Escherichia coli and refolded from inclusion bodies. Biophysical studies and mutational analysis of the protein indicate that it is folded into the desired neutral pH conformation competent to bind the broadly neutralizing HA2 directed monoclonal 12D1, not the low pH conformation observed in previous studies. HA6 was highly immunogenic in mice and the mice were protected against lethal challenge by the homologous A/HK/68 mouse-adapted virus. An HA6-like construct from another H3 strain (A/Phil/2/82) also protected mice against A/HK/68 challenge. Regions included in HA6 are highly conserved within a subtype and are fairly well conserved within a clade. Targeting the highly conserved HA2 subunit with a bacterially produced immunogen is a vaccine strategy that may aid in pandemic preparedness.

[1]  R. Varadarajan,et al.  Mutagenesis-based definitions and probes of residue burial in proteins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Air,et al.  Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Varadarajan,et al.  Identification and thermodynamic characterization of molten globule states of periplasmic binding proteins. , 2007, Biochemistry.

[4]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[5]  A. Osterhaus,et al.  Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region , 2000, Archives of Virology.

[6]  M. Cox Cell-based protein vaccines for influenza. , 2005, Current opinion in molecular therapeutics.

[7]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[8]  J. Skehel,et al.  Variation and infectivity neutralization in influenza , 2006, Immunology.

[9]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[10]  W. Gerhard The role of the antibody response in influenza virus infection. , 2001, Current topics in microbiology and immunology.

[11]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[12]  Yoshihiro Kawaoka,et al.  Influenza: lessons from past pandemics, warnings from current incidents , 2005, Nature Reviews Microbiology.

[13]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[14]  E. Ooi,et al.  Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library , 2008, Virology Journal.

[15]  Y. Isegawa,et al.  Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains , 1994, Journal of virology.

[16]  F. Kostolanský,et al.  Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. , 2008, The Journal of general virology.

[17]  A. Sánchez-Fauquier,et al.  Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits , 2005, Archives of Virology.

[18]  J. Skehel,et al.  Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. , 1994, Biochemistry.

[19]  A. Mitra,et al.  High level expression of peptides and proteins using cytochrome b5 as a fusion host. , 2005, Protein expression and purification.

[20]  J. Skehel,et al.  Mechanism of neutralization of influenza virus infectivity by antibodies. , 2002, Virology.

[21]  R A Sayle,et al.  RASMOL: biomolecular graphics for all. , 1995, Trends in biochemical sciences.

[22]  Y. Iba,et al.  Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. , 2010, Virology.

[23]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[24]  W. Weissenhorn,et al.  A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[26]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[27]  D. Baker,et al.  Design of a Novel Globular Protein Fold with Atomic-Level Accuracy , 2003, Science.

[28]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[29]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[30]  Raghavan Varadarajan,et al.  MODIP revisited: re-evaluation and refinement of an automated procedure for modeling of disulfide bonds in proteins. , 2003, Protein engineering.

[31]  J. Udgaonkar,et al.  Stabilization of barstar by chemical modification of the buried cysteines. , 1996, Biochemistry.

[32]  J. Skehel,et al.  Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity , 1992, Cell.

[33]  David J Stevens,et al.  Structure of the Hemagglutinin Precursor Cleavage Site, a Determinant of Influenza Pathogenicity and the Origin of the Labile Conformation , 1998, Cell.

[34]  I. Wilson,et al.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation , 1981, Nature.

[35]  R. Varadarajan,et al.  Protein minimization of the gp120 binding region of human CD4. , 2005, Biochemistry.

[36]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[37]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[38]  Rahul Raman,et al.  Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift , 2009, Science.

[39]  Raghavan Varadarajan,et al.  Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design , 2005, Journal of Virology.

[40]  N. Cox,et al.  Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites , 1983, Journal of virology.

[41]  J. Shiver,et al.  Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro , 2002, The Journal of Biological Chemistry.